These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients. Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683 [TBL] [Abstract][Full Text] [Related]
46. Influence of subinhibitory concentrations of protein-synthesis-inhibiting antibiotics on production and release of the pneumococcal virulence factor pneumolysin in vitro. Spreer A; von Ruden C; Mitchell TJ; Eiffert H; Nau R Chemotherapy; 2007; 53(5):327-31. PubMed ID: 17728540 [TBL] [Abstract][Full Text] [Related]
47. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Elliott DJ; Zaoutis TE; Troxel AB; Loh A; Keren R Pediatrics; 2009 Jun; 123(6):e959-66. PubMed ID: 19470525 [TBL] [Abstract][Full Text] [Related]
50. Effects of diesel exhaust particles on human alveolar macrophage ability to secrete inflammatory mediators in response to lipopolysaccharide. Mundandhara SD; Becker S; Madden MC Toxicol In Vitro; 2006 Aug; 20(5):614-24. PubMed ID: 16360300 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. McKinnon PS; Paladino JA; Schentag JJ Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273 [TBL] [Abstract][Full Text] [Related]
52. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections. Appelbaum PC Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544 [TBL] [Abstract][Full Text] [Related]
53. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Tan XX; Actor JK; Chen Y Antimicrob Agents Chemother; 2005 Aug; 49(8):3203-7. PubMed ID: 16048926 [TBL] [Abstract][Full Text] [Related]
54. Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation. Dessing MC; Schouten M; Draing C; Levi M; von Aulock S; van der Poll T J Infect Dis; 2008 Jan; 197(2):245-52. PubMed ID: 18179383 [TBL] [Abstract][Full Text] [Related]
55. The innate immune response to secondary peritonitis. van Till JW; van Veen SQ; van Ruler O; Lamme B; Gouma DJ; Boermeester MA Shock; 2007 Nov; 28(5):504-17. PubMed ID: 17589378 [TBL] [Abstract][Full Text] [Related]
56. Staphylococcal peptidoglycan initiates an inflammatory response and procoagulant activity in human vascular endothelial cells: a comparison with highly purified lipoteichoic acid and TSST-1. Mattsson E; Heying R; van de Gevel JS; Hartung T; Beekhuizen H FEMS Immunol Med Microbiol; 2008 Jan; 52(1):110-7. PubMed ID: 18031538 [TBL] [Abstract][Full Text] [Related]
57. Effects of the Escherichia coli toxin cytolysin A on mucosal immunostimulation via epithelial Ca2+ signalling and Toll-like receptor 4. Söderblom T; Oxhamre C; Wai SN; Uhlén P; Aperia A; Uhlin BE; Richter-Dahlfors A Cell Microbiol; 2005 Jun; 7(6):779-88. PubMed ID: 15888081 [TBL] [Abstract][Full Text] [Related]
58. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome. Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911 [TBL] [Abstract][Full Text] [Related]
59. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. Stevens DL; Ma Y; Salmi DB; McIndoo E; Wallace RJ; Bryant AE J Infect Dis; 2007 Jan; 195(2):202-11. PubMed ID: 17191165 [TBL] [Abstract][Full Text] [Related]
60. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Bradford PA; Weaver-Sands DT; Petersen PJ Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]